Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The purpose of the AMALFI study is to see whether wearing a new home monitor called a Zio Patch, which can give a continuous heart trace reading for 2 weeks, will increase the number of people we can detect with atrial fibrillation. Diagnosing atrial fibrillation is normally done using an electrocardiogram (ECG) which catches the heart rate at a single point in time. However, as atrial fibrillation may only be happening some of the time this test might not always detect atrial fibrillation if by chance the heart is beating regularly when the ECG is done. The hope is that using the Zio Patch would allow more people to be put on the right treatment at an earlier stage and so bring down their risk of having a stroke.